LAVA Therapeutics (NASDAQ:LVTX) Given “Buy” Rating at HC Wainwright

LAVA Therapeutics (NASDAQ:LVTX)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $6.00 target price on the stock. HC Wainwright’s price target suggests a potential upside of 219.15% from the company’s previous close.

LAVA Therapeutics Stock Up 1.6 %

LVTX stock opened at $1.88 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.42 and a quick ratio of 7.42. The company’s 50-day moving average price is $2.54 and its two-hundred day moving average price is $2.33. LAVA Therapeutics has a 12 month low of $1.13 and a 12 month high of $6.47.

LAVA Therapeutics (NASDAQ:LVTX) last announced its quarterly earnings data on Tuesday, May 21st. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.23. The business had revenue of $6.99 million during the quarter. LAVA Therapeutics had a negative net margin of 228.02% and a negative return on equity of 51.90%. On average, analysts predict that LAVA Therapeutics will post -1.3 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in LAVA Therapeutics stock. Pathway Financial Advisors LLC acquired a new position in shares of LAVA Therapeutics (NASDAQ:LVTX) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 14,000 shares of the company’s stock, valued at approximately $47,000.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.